Ozempic is now FDA-approved to reduce chronic kidney disease risks in diabetes patients. A Phase 3 trial showed Ozempic reduced kidney disease worsening by 24% and heart-related deaths by 5%.

The FDA has approved Ozempic to help lower chronic kidney disease-related risks in people with type 2 diabetes. The findings of a recent clinica trial, funded by drugmaker Novo Nordisk, indicate ...

EU regulator supports a label expansion of Novo Nordisk’s diabetes drug to reflect its potential to lower the risk of conditions related to kidney disease in adults with Type 2 diabetes.

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...

The post FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients appeared first on East Idaho News.

Ozempic has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney disease, drugmaker Novo Nordisk said Tuesday.

It also reduced the risk of kidney failure and cut the risk of death from heart disease by about 5% in adults with both type 2 diabetes and chronic kidney disease, the company said in a news release.

(CNN) — Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks ...